Abstract: A system may use a machine-learned model to determine whether to classify a sequence of one or more words within a first document that is being edited as a candidate hyperlink based at least in part on context associated with the first document. In response to classifying the sequence of one or more words as the candidate hyperlink, the system may use the machine-learned model and based at least in part on the sequence of one or more words and the context to determine one or more candidate document to be hyperlinked from the sequence of one or more words. In response to receiving an indication of a second document being selected out of the one or more candidate documents, the system may modify the first document to associate the sequence of one or more words with a hyperlink to the second document.

Abstract: A system may use a machine-learned model to determine whether to classify a sequence of one or more words within a first document that is being edited as a candidate hyperlink based at least in part on context associated with the first document. In response to classifying the sequence of one or more words as the candidate hyperlink, the system may use the machine-learned model and based at least in part on the sequence of one or more words and the context to determine one or more candidate document to be hyperlinked from the sequence of one or more words. In response to receiving an indication of a second document being selected out of the one or more candidate documents, the system may modify the first document to associate the sequence of one or more words with a hyperlink to the second document.

Abstract: The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.

Abstract: The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.

Abstract: The invention provides the use of a non-steroid compound which acts on the GABA receptor for the treatment of disorders relating to reduced neurosteroid activity. The non-steroid compounds may be GABA agonists, GABA uptake inhibitors or enhancers of GABAergic activity.

Abstract: The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition.

Abstract: The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.

Abstract: The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to a method of treating a disease wherein one or more inflammatory markers are increased, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that enhances GABAA-ergic neurotransmission.

Abstract: The present invention relates to the use of gaboxadol for the preparation of medicaments useful for the treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis.

Abstract: The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.

Abstract: The present invention relates to novel medical applications of down-regulation of tumour necrosis factor ? (TNF-?) activity, especially novel applications of active immunization against TNF-a in order to reduce or alleviate pain. In particular, the present invention discloses novel methods for treating or ameliorating neuropathic pain.

Abstract: The present invention concerns a method for treating insomnia in a human subject in need thereof by administering to said subject an amount of gaboxadol per day, said amount being effective for the treatment of insomnia. In various preferred embodiments, the effective amount is from 5 to 15 mg gaboxadol in oral dosage form, administered from one hour before up until bedtime.

Abstract: The invention provides the use of a non-steroid compound which acts on the GABA receptor for the treatment of disorders relating to reduced neurosteroid activity. The non-steroid compounds may be GABA agonists, GABA uptake inhibitors or enhancers of GABAergic activity.